498 related articles for article (PubMed ID: 9065993)
1. Blood coagulation and thrombosis in patients with ovarian malignancy.
von Tempelhoff GF; Dietrich M; Niemann F; Schneider D; Hommel G; Heilmann L
Thromb Haemost; 1997 Mar; 77(3):456-61. PubMed ID: 9065993
[TBL] [Abstract][Full Text] [Related]
2. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
3. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.
Prandoni P; Villalta S; Bagatella P; Rossi L; Marchiori A; Piccioli A; Bernardi E; Girolami B; Simioni P; Girolami A
Haematologica; 1997; 82(4):423-8. PubMed ID: 9299855
[TBL] [Abstract][Full Text] [Related]
4. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin.
Boncinelli S; Marsili M; Lorenzi P; Fabbri LP; Pittino S; Filoni M; Bressan F; Sarti E; Cinotti S; Morfini M
Minerva Anestesiol; 2001 Oct; 67(10):693-703. PubMed ID: 11740417
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic defense during the postoperative period. Clinical documentation of low molecular weight heparin.
Welzel D; Wolf H; Koppenhagen K
Arzneimittelforschung; 1988 Jan; 38(1):120-3. PubMed ID: 2835055
[TBL] [Abstract][Full Text] [Related]
6. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery.
Ginsberg JS; Brill-Edwards P; Panju A; Patel A; McGinnis J; Smith F; Dale I; Johnston M; Ofosu F
Thromb Haemost; 1995 Aug; 74(2):602-5. PubMed ID: 8584991
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures.
Pini M; Tagliaferri A; Manotti C; Lasagni F; Rinaldi E; Dettori AG
Int Angiol; 1989; 8(3):134-9. PubMed ID: 2556484
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery.
Koppenhagen K; Adolf J; Matthes M; Tröster E; Roder JD; Hass S; Fritsche HM; Wolf H
Thromb Haemost; 1992 Jun; 67(6):627-30. PubMed ID: 1324534
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
14. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
[TBL] [Abstract][Full Text] [Related]
15. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
16. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
[TBL] [Abstract][Full Text] [Related]
18. Management of thromboembolism in patients with cancer.
Viale PH
Oncol Nurs Forum; 1999; 26(10):1625-32; quiz 1633-4. PubMed ID: 10573679
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of deep vein thrombosis by enoxaparin after total hip prosthesis].
Vochelle N; Planes A
Agressologie; 1990 Mar; 31(3):145-8. PubMed ID: 2173435
[TBL] [Abstract][Full Text] [Related]
20. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
